InstructorRoyed Training
TypeOnline Course
Student Enrolled2
Price$590 / 41300 INR.
Buy NowBook Now
Loading
Loading
European Drug Regulatory Affairs course by royed training

uropea

Introduction

who should attend

Feature

Related Courses

Core Topics

EU drug regulatory affairs course

The objective of European (EU) Drug Regulatory Affairs course is to provide training on marketing authorization approval in European Union.

EU regulatory affairs course covers recent pharmaceutical regulations, marketing authorization procedure, country specific Common Technical Documents requirement. Moreover, comprehensive ideas are provided on how to prepare drug dossiers as per EU CTD format. Moreover the course focuses on the various marketing authorization pathways. Above all, course briefs on strategic planning for registration of pharmaceutical, biopharmaceuticals in the European Union.

This online course utilizes interactive learning tools to guide each participant through to understand the EU regulatory structure and ensure that your submissions meet the standards required by the regulators. The course will focus on understanding the European legal & regulatory environment; the registration procedures that are available, and the structure of the registration dossier. Moreover the course will adopt a practical and interactive approach that will enable you to apply what you have learned to your daily work. Above all, the course will also provides hands on training on approval process in detail.

The course is designed to challenge students to apply what they have learned through the use of interactive exercises, reflection questions, expert live chat and a final assessment at the end of the course.

Course Snapshot

  • Course Code: RYD-011
  • Title of the course: Advance Certification in European Drug Regulatory Affairs (ACEUDRA)
  • Nature of the course: Online self paced learning course. Hence, course can be accessed 24×7, across anywhere.
  • Duration of the course: 1 Month.
  • Eligibility: Any body who wants to acquire EU drug regulatory affairs competency should attend the course.
  • Course certificate : Certificate will be provided at the end of the successful completion of the course.

Who should attend?

  • Regulatory Affairs professionals who are seeking to improve their skills in the European Drug Regulatory environment.
  • Those moving into regulatory affairs from other areas within a pharmaceutical company (Pharmacists, Clinical Trials, Marketing and others).
  • Anyone wishing to update their knowledge on European regulatory affairs.
  • Regulatory Affairs, Registration and Documentation assistants/officers/managers.
  • Above all, this course is ideal for the business development managers working in pharmaceutical companies, who are handling pharmaceutical business in the European Union.

This European Drug Regulatory Affairs online course utilizes interactive learning tools to guide each participant through to understand the regulatory process of the EU pharmaceutical market. This online certification course will focus on understanding regulatory affairs strategic management skills which is required for effective functioning as regulatory personnel. Indeed, advanced simulation in the course will challenge students to apply what they have learned from the course. In addition, there are advanced learning tools like interactive exercises, reflection questions, and expert live chat which makes the course very interesting.

Key features of the course

  • Orientation to practical understanding in the entire drug regulation, registration procedure of the European Union. Moreover, the course also focuses on Common Technical Documents, guidelines and drug dossier preparations.
  • The course is self paced. Hence, courses can be accessed 24×7, anytime, anywhere across the globe.
  • Moreover, students can download the course material handed out by login to the dashboard. Hence, it helps them to study offline even after completion of the course.
  • Final examination is online. Hence, students can attend the final certification examination at their own convenient date and time.

At Royed Training, we have dedicated International Drug Regulatory Affairs course which covers European Drug Regulatory Affairs course. Executive program in International Drug Regulatory Affairs course covers US, EU, Japan, LATAM, ASEAN, AFRICAN, Middle East / GCC regulation in a single comprehensive course.

Few of the similar courses

European Drug Regulatory Affairs course covers a range of topics related to regulatory affairs in the pharmaceutical and biotechnology industries in Europe. Here are some common areas and subjects that might be included:

Introduction to Regulatory Affairs:

  • Overview of drug development and the role of regulatory affairs.
  • Regulatory agencies and authorities in Europe (e.g., EMA – European Medicines Agency).

European Regulatory Strategic Planning:

  • Developing regulatory strategies for different stages of drug development
  • Regulatory pathways for different types of drugs (e.g., small molecules, biologics, generics, biosimilars).

Submissions Training:

  • Preparing and submitting applications for marketing authorization (MAA) and also variation management.
  • Understanding the Common Technical Document (CTD) format, CMC writing and skill enhancer training on submission management process.

Clinical Development and Trials:

  • Clinical trial regulations in Europe (e.g., GCP – Good Clinical Practice).
  • Investigational Medicinal Product Dossier (IMPD) and Clinical Trial Application (CTA) submissions.

Quality and Manufacturing:

  • GMP (Good Manufacturing Practice) regulations and compliance.
  • Quality control, quality assurance, and quality management systems.

Pharmacovigilance and Post-Marketing Surveillance:

  • Adverse event reporting and pharmacovigilance requirements.
  • Risk management plans and post-marketing studies.

Regulatory Updates and Emerging Trends:

  • Keeping up with changes in European regulatory guidelines and legislation.
  • Exploring emerging trends in regulatory affairs, such as digital health and real-world evidence.

Regulatory Compliance and Inspections:

  • Preparing for regulatory inspections and audits.
  • Ensuring ongoing compliance with regulatory requirements.
Section 1EU Regulation
Lecture 1EU Regulatory System Fundamentals
Lecture 2Introduction to EU Regulation 
Lecture 3Orientation to European Countries and National Regulatory Bodies
Lecture 4EMA and EMA Authorisation Process
Lecture 5EMA and EMA Authorisation Process
Lecture 6Centralised vs DCP vs MRP vs National Procedure - Detailed Strategic Insight
Lecture 7EU MA Application Types and Strategic Planning
Lecture 8EU MA Procedure - Centralised, Decentralised, Mutual Recognition, National Procedure 
Lecture 9EU MA Strategic Planning: Full, Full-mixed, hybrid applications. Generic, Similar biologic application pathway, Well-established use application, Fixed combination application, Informed consent application
Lecture 10Validity of the EU MA  - Renewal steps, Cessation of the marketing authorisation, Significance of "Placed in Union Market", Suspension or withdrawal & EU MA for licensed products
Lecture 11Structured Practical understanding of EU legal bases | Understanding Data Requirements
Lecture 12Practical understanding of EU legal bases for Marketing Authorisation Applications (MAA) | Decision Tree
Lecture 13Centralised Procedure Timetable and Review Logic
Lecture 14DCP / MRP / National Procedure – Practical Workflow Module
Lecture 15EU Procedures Critical Operational Steps - Validation • Clock-Stop • List of Questions • Approval • National Phase
Lecture 16DCP vs MRP Timeline 
Lecture 17EU Adaptive Pathway
Lecture 18European public assessment report (EPAR) - Importance, Component, Management, Updation 
Lecture 19SPOR  - Concept of Master Data Management
Lecture 20The 'sunset clause' for marketing authorisation of pharmaceuticals
Lecture 21LoQ Response Strategy - EU Regulatory Procedures (CP / DCP / MRP) – Winning the Day 120 / Mid-Cycle Response
Lecture 22Response to list of Questions (LoQ)
Lecture 23Response to list of outstanding issues  (LoOI) - Day 180 / Final Assessment Phase Response
Lecture 24Oral Explanation Training Module - CHMP / CMDh Oral Defence Strategy – From Data to Approval
Lecture 25CHMP - Question Bank  Real-Life Regulatory Questions + Model Answers (CP / DCP / MRP)
Lecture 26Conditional marketing authorisation | Marketing authorisation under exceptional circumstances
Lecture 27Compassionate Use
Lecture 28EU Prime Designation 
Lecture 29MHRA - UK Regulation 
Lecture 30Summary of Product Characteristics 
Lecture 31Drug Registration and Submission Strategic Planning for Russia and EAEU region
Lecture 32Accelerated assessment by EMEA
Lecture 33Certificate of Suitability (CEP) | Significance | Importance | Understanding Regulatory Compliance and Submission Process | Walkthrough
Lecture 34CEP Dossier DMF - Differences
Lecture 35Policy 0070 |  RPDP Submission and Management timeline | Anonymisation Report (AnR) - Significance | AnR in FRDP 
Section 2Clinical Trial & Research
Lecture 36Comprehensive EU Clinical Trial Regulatory Affairs – CTA, CTIS, Strategy & Execution
Lecture 37CTIS Operating Model – Advanced EUClinical Trial Execution Module
Lecture 38CTA Structure: Part I / Part II (EU Clinical Trials Regulation)
Lecture 39Country-wise Part II Requirement Master
Lecture 40CTIS Hands-on Simulation Module Step-by-Step Clinical Trial Submission Exercise (CTR Execution Training)
Lecture 41EU CTR Advanced Module - Substantial Modifications, Safety Reporting, Transition Lessons & End-of-Trial Obligation
Lecture 42IMPD | Significance | Format of IMPD | Differences with CTA, IB, IND
Lecture 43Investigator’s Brochure | Significance | Format of IB | Preparing different sections of IB
Section 3Dossier Preparation
Lecture 44Patent Landscape & Freedom to Operate (FTO) – EU Perspective - Strategic Regulatory + IP Integration Module (Drugs & Biologics)
Lecture 45EU Data Exclusivity, Market Protection & Orphan Exclusivity
Lecture 46Chemistry, Manufacturing & Controls 
Lecture 47EU Orphan Medicinal Products Regulation
Lecture 48Paediatric use marketing authorisation (PUMA) & Paediatric Investigation Plan (PIP)
Lecture 49EU Supplementary Protection Certificates (SPC) & Paediatric Rewards
Lecture 50Patent vs Regulatory Exclusivity vs Trademark vs Launch Sequencing (EU Perspective)
Lecture 51“No EU-Style Patent Linkage” – What It Really Means (EU vs US)
Lecture 52EU vs US Regulatory–IP Framework
Lecture 53Global Patent + Exclusivity Timeline Dashboard - Executive-Level Strategic Tool (EU + US + Global Integration)
Lecture 54Full EU Submission Strategy Planner
Section 4Pharmacovigilance Program
Lecture 55Introduction to Pharmacovigilance |Definition| Importance |Focus Area | Regulatory compliance | PV activities 
Lecture 56Introduction to ADR | Definition | Importance of ADR management | Classification | Prevention of ADR
Lecture 57Terminologies related to ADR 
Lecture 58ADR Reporting System | ADR information loop | ADR reporting system in various countries
Lecture 59DoTS
Lecture 60PSUR
Lecture 61ADR Seriousness Determination 
Lecture 62How regulatory body adopt PV Program in EU?
Lecture 63PSUR
Section 5Recent Update - Brexit
Section 6Drug Registration and Submission Strategic Planning for Russia and EAEU region
Lecture 65Drug Registration and Submission Strategic Planning for Russia and EAEU region
Lecture 66GMP requirements in Russia 
Section 7Bioequivalence Study
Lecture 67PKPD in Drug Discovery | PK-PD trial | Understanding PKPD from regulatory perspective in drug approval process
Lecture 68Bioequivalence Study | Study design | Different types of BE Studies
Lecture 69Bioequivalence Study | Study design | Parallel Study | Crossover study design | Other alternative study designs | Blood Sampling Planning  | Analyte | Bioanalytical Methods Validation  | Statistical Model  | Ln Transformation  | Dose normalisation | Confidence interval acceptance criteria
Lecture 70Biopharmaceutical Classification System (BCS) | Types | Biowaivers | BCS tool for drug development and regulatory submission 
Lecture 71Bioequivalence Study - Discussion - Timeline of stability study and bioequivalence study 
Lecture 72Bioequivalence Study - Discussion - Dissolution Testing
Lecture 73Bioequivalence Study - Generic Approval and Additives Labeling Requirements 
Section 8EU Variation Management
Lecture 74EU Variations Legal Framework (Drugs & Biologics) - With Country-Specific Requirements & Operational Differences
Lecture 75Variation Classification | Basis of Classification | US and EU Variation Classification | Other region variation guideline
Lecture 76EU variation -Types, Requirement & Planning - IA, IAIN, IB, II ; US FDA Variation AR, CBE-0, CBE-30, PAS - Strategic Discussion | Similarities & Differentiation
Lecture 77EU Variations Classification – Type IA / IAIN / IB / Type II / Extensions (Line Extensions) - Deep Regulatory Training Module (Execution-Level Understanding)
Lecture 78EU Variation Classification Decision Matrix - Type IA / IAIN / IB / Type II / Extension – Structured Decision Framework
Lecture 79EU Variations: Grouping, Super-Grouping & Worksharing
Lecture 80EU Variations: Centralised vs MRP/DCP vs National – Mechanics & Execution - End-to-End Operational Module
Lecture 81EU Variations – Country-Specific Implementation Issues - Critical Post-Approval Execution Module
Lecture 82EU Variation Impact Dashboard 
Lecture 83Country Wise Variation Tracker (EU focussed)
Lecture 84EU Variation Country Roll out planner
Lecture 85EU Variation Roll Out - Command Center Dashboard 
Lecture 86EU Variations – Invalidation Risks & Day 0 Failures - Critical Regulatory Risk Control Module
Section 9EU CCDS Management | PI | PIL | Regulatory Requirements for Labels
Lecture 87Regulatory vs Commercial Perspective of Labelling | Labelling Compliance Function 
Lecture 88Types of Labels 
Lecture 89Artwork & Packaging Lifecycle | Artwork Management Lifecycle Workflow 
Lecture 90Global Artwork Labelling Framework | 5 Case Simulation
Lecture 91Country-Specific Labelling Requirements
Lecture 92Summary of Product Characteristics (SmPC) 
Lecture 93Patient Information Leaflet (PIL)
Lecture 94Summary of Product Characteristics (SmPC) – Review Checklist
Lecture 95Patient Information Leaflet (PIL) – Review Checklist
Lecture 96PI Vs. Medication Guide Comparison 
Lecture 97Patient Information Leaflet (PIL) vs Medication Guide 
Lecture 98Label Components | Key considerations for effective designing of label 
Lecture 99Label Review Checklist 
Lecture 100Post approval Labelling | PAS | CBE-30 | Annual Reportable Changes
Lecture 101CCDS Management 
Lecture 102CCDS Management Tools - Native, AI Plus | Key Functionalities
Lecture 103AI Augmented Labelling Compliance System
Lecture 104Label Drift in CCDS Management | Simulation Case Study | AI Based Workflow in Label Drift detection and management
Lecture 105AI Review of Labels, PI and SMPC with help of the Case Based Simulation | 4 Case Simulations 
Lecture 106CCDS Management Case Study | Pregnancy Warning Upgrade Case Study
Lecture 107CCDS Management Case Study | Dosage Section Conflict | Case Based Analysis
Lecture 108Centralized Artwork Operation | Mechanism | Operation Step Planning 
Lecture 109Case Study on Centralized Artwork Operation  [Recall Management]
Lecture 110Artwork Management Terms | Key Understanding on Terminologies | Usage in Artwork Cases
Lecture 111Source Documents | Artwork Brief
Lecture 112Creating and Reviewing Label Content | Stakeholders of Labelling and Artwork Management | Case Studies